FX-111A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor:

Flare Therapeutics Inc.

Code:

NCT07719361

Conditions

Metastatic Castration Resistant Prostate Cancer

mCRPC

mCRPC (Metastatic Castration-resistant Prostate Cancer)

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

FX-111

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Flare Therapeutics Inc. on 2026-08-04.